

Ontario Health Recommendations for Outpatient Use of Intravenous Remdesivir (Veklury) in Adults

Date: September 15, 2023

This document was developed by Ontario Health’s Infectious Diseases Advisory Committee based on best available evidence and expert consensus. There are limitations to the evidence that is currently available. **Prescribers must determine whether adopting suggested information is clinically appropriate for individual patients through a comprehensive risk-benefit assessment.**

Purpose

The objective of this document is to provide recommendations to guide clinicians on appropriate prescribing of intravenous (IV) remdesivir to adults (≥ 18 years) who can receive treatment in an **outpatient setting** (e.g., community nursing clinic) for coronavirus disease 2019 (COVID-19).

Evidence Summary for the Outpatient Use of Remdesivir

Evidence to support outpatient IV remdesivir treatment is largely based on a single randomized, double-blind, placebo-controlled trial (PINETREE) in unvaccinated, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) positive, high-risk patients ($n=562$) who had symptom onset within the previous **seven** days, at least one risk factor for disease progression or age ≥ 60 years (regardless of other factors). Patients were randomized to receive a 3-day course of IV remdesivir ($n= 279$) or placebo ($n=283$). The most common underlying conditions were diabetes mellitus, obesity, and hypertension. The risk of COVID-19–related hospitalization or death from any cause by day 28 was 87% lower in the remdesivir group than in the placebo group (HR: 0.13; 95% CI, 0.03 to 0.59; $P = 0.008$). Remdesivir was well tolerated with mild nausea, headache, and cough being the most common side effects. ¹ A subsequent sub-group analysis in 2023 evaluated the efficacy of remdesivir by time from symptom to treatment initiation and by the number of baseline risk factors. Efficacy was maintained for patients starting at > 5 days from symptom onset and for treating patients with low numbers (≤ 2) or high number of risk factors (≥ 3) for severe COVID-19). ²

The data from the PINETREE study is limited because several high-risk groups were underrepresented (e.g., only 5% of study patients were immunocompromised), the study population was unvaccinated, and it was conducted prior to the emergence of Omicron and its sub-variants. Subsequent prospective, observational and retrospective real-world studies have evaluated outpatient remdesivir in these underrepresented high-risk groups, in the setting of high vaccination rates, and since the emergence of Omicron. Overall, these studies varied in their definitions of “high risk”, and hospitalization rates and deaths with the use of remdesivir varied between studies. However, since the emergence of Omicron and its sub-variants, evidence has accumulated to demonstrate that remdesivir is safe and effective for outpatient treatment of COVID-19

in vaccinated patients.³⁻¹⁰ Remdesivir also appears to be clinically comparable to nirmatrelvir/ritonavir in a vaccinated population with at least one risk factor for severe COVID-19 during Omicron.^{5,6}

Immunocompromised individuals may have diminished responses to COVID-19 vaccines and are also at higher risk for prolonged infections and complications from SARS-CoV-2 infection.¹¹ For immunocompromised patients, data from retrospective and prospective studies demonstrated that remdesivir reduced the risk of hospitalization or death, even in the setting of high vaccination rates and Omicron.^{4,7,9,10,12,13} These studies included patients with solid organ transplant, hematologic malignancies, hematopoietic stem cell transplants, and autoimmune diseases.

Additional studies have described models of administering IV remdesivir in the outpatient setting. They have demonstrated that outpatient administration (including at-home administration) is feasible and safe.¹⁴⁻¹⁶

Recommendations

In Canada, both intravenously administered remdesivir (Veklury®) and orally administered nirmatrelvir/ritonavir (Paxlovid®) are Health Canada approved therapies for treatment of non-hospitalized patients with mild to moderate COVID-19 with a high risk of progression to severe COVID-19 (see **Table 1**). Randomized and observational evidence demonstrates that both these therapies can reduce hospitalizations and death. To date, there are no randomized controlled studies that directly compare these two therapies. In general, choice of anti-viral therapy is based on patient-specific factors (e.g., medical contraindications, significant drug-drug interactions), time from symptom onset, availability of the therapy, and feasibility of administration.¹⁷⁻¹⁹

The following consensus-based recommendations were informed by evidence retrieved from a systematic literature search conducted in May 2023 and available Canadian/international guidelines.¹⁷⁻³²

Considering the best available evidence and health system factors, the Committee made the following recommendations (See **Figure 1** for a suggested treatment algorithm):

- 1. Patients must be at high risk for hospitalization or death due to COVID-19.**

Antivirals (nirmatrelvir/ritonavir or remdesivir) are indicated in outpatients with mild to moderate COVID-19 symptoms who are at **high risk** of hospitalization or death due to COVID-19. (See section on identification of high-risk patients below). Mild-to-moderate respiratory illness includes fever and one or more clinical findings of lower respiratory illness (e.g., cough, shortness of breath, and breathing difficulties).³¹

- 2. A COVID-19 diagnosis is required prior to initiating antiviral therapy.**

Patients must have COVID-19 symptoms and a positive test for SARS-CoV-2 based on PCR, rapid molecular, or rapid antigen test to be considered for outpatient nirmatrelvir/ritonavir or remdesivir therapy.

3. Nirmatrelvir/ritonavir is the preferred first-line therapy when safe and feasible.

Nirmatrelvir/ritonavir is the **preferred** outpatient therapy for treating patients with *mild to moderate* COVID-19 who are at **high risk** of severe COVID-19, regardless of vaccination status or prior COVID-19 infection due to the feasibility of administration:

- Therapy must be initiated within **5 days** of symptoms onset.
- Nirmatrelvir/ritonavir tablets can be crushed. A feeding tube is not an absolute contraindication to use.^{33,34}
- For patients with renal impairment or on dialysis, doses can be adjusted.
- **Assess for drug-drug interactions. Prior to considering remdesivir, ensure that drug-drug interactions with nirmatrelvir/ritonavir cannot be safely mitigated.** Mitigating strategies include dose reductions and/or short-term treatment interruption. Consult with specialists as required (e.g., oncology, transplant). Consultation with a pharmacist who can obtain a complete medication, recreational, and natural health product history from the patient is recommended. (*See Table 1 for suggested resources*).

4. Remdesivir is indicated where nirmatrelvir/ritonavir is contraindicated (e.g., drug-drug interaction that cannot be safely managed, medical contraindication) or when patients are beyond the treatment window for nirmatrelvir/ritonavir initiation (i.e., symptom onset > 5 days).

- Initiation of therapy within 7 days of symptom onset is recommended.
(*Given the lack of evidence, initiation beyond this date should only be considered based on clinical judgement.*)
- Patients need to be able to receive **three days of consecutive IV** therapy (Consider travel requirements or other delivery barriers that may exist).
- The use of beta-blockers is not a contraindication to using remdesivir. (*See Table 1*)

Guidance for Identifying Patients at High Risk for Severe COVID-19

Defining a high-risk population is challenged by the evolving nature of the SARS-CoV-2 virus. Evidence continues to emerge to inform risk assessments. In general, older age is the strongest risk factor for severe outcomes due to COVID-19.²⁰ Other risk factors include being immunocompromised, unvaccinated or under vaccinated, or having one or more underlying medical conditions.^{17,20,27} Patients with multiple risk factors have a higher risk of severe COVID-19, and are most appropriate for antiviral therapy.

“**High-risk**” patients who may be considered for antiviral therapy include:

1. **Adults ≥ 60 years of age, regardless of vaccination status, with no other risk factors.**
2. **Adults who are immunocompromised, regardless of age, vaccine status, or prior infections.**
e.g., active hematological malignancy or post stem cell transplant or CAR T-cell therapy in last 6 months, solid organ transplant, hypogammaglobulinemia, taking prednisone >20 mg/day (or equivalent) for more than 14 days, or other moderately or severely immunosuppressive therapies (e.g., anti-CD20 agents, alkylating agents, cancer chemotherapy),

3. Adults with inadequate immunity, i.e.,

- Unvaccinated or under-vaccinated (*e.g., completed primary series AND last COVID-19 vaccine dose was more than 6 months ago AND last SARS-CoV-2 infection was more than 6 months ago*)
 - See the most recent [immunization guidance](#) from National Advisory Committee on Immunization to determine if your patient is under-vaccinated

4. Adults with one or more underlying conditions that puts them at high risk for severe COVID-19 outcomes.

The US Centers for Disease Control and Prevention maintains an evidence-informed list of underlying medical conditions associated with severe COVID-19.²⁰ Based on the current list, the Committee highlighted the following high-risk medical conditions:

- Cerebrovascular disease
- Chronic kidney disease – including people receiving dialysis
- Chronic lung diseases limited to: Asthma, Bronchiectasis, COPD (Chronic obstructive pulmonary disease), Interstitial lung disease, Pulmonary embolism, Pulmonary hypertension
- Chronic liver diseases limited to: Cirrhosis, Non-alcoholic fatty liver disease, Alcoholic liver disease, Autoimmune hepatitis
- Cystic fibrosis
- Diabetes mellitus (type 1 and 2)
- Disabilities and developmental delay, including Down syndrome
- Heart conditions (such as heart failure, coronary artery disease, or cardiomyopathies)
- Mental health conditions limited to: Mood disorders (including depression), Schizophrenia spectrum disorders
- Neurologic conditions that cause an inability to control respiratory secretions or to communicate disease progression. *e.g., cognitive disorders such as Alzheimer’s type dementia*
- Obesity (BMI >30 kg/m² or >95th percentile in children)
- Pregnancy and recent pregnancy (42 days post-partum/end of pregnancy)
- Smoking, current and former
- Tuberculosis

Individuals who are at a higher risk of poor outcomes from COVID-19 based on social determinants of health should be considered priority populations for access to antivirals. Individuals with certain medical or social vulnerabilities may experience challenges in recognizing, communicating or acting on progressing COVID-19 symptoms.³⁵ Individuals at higher risk include Indigenous people, Black people, other members of racialized communities people who are underhoused, individuals with intellectual, developmental, or cognitive disability, people who use substances regularly (*e.g., alcohol*) and/or live with mental health conditions.^{20,35–}

42


Table 1: Overview of recommended therapies for mild to moderate COVID-19

	Nirmatrelvir/Ritonavir (Paxlovid)	Remdesivir (Veklury)
Place in Therapy	Preferred first line therapy	Alternative to nirmatrelvir/ritonavir
Indication(s) <i>(Health Canada approved)</i>	Treatment of mild-to-moderate COVID-19 in <i>adults</i> with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death. ⁴³	<ul style="list-style-type: none"> Hospitalized adults and adolescents (aged 12 years to less than 18 years who weigh at least 40 kg) with pneumonia requiring supplemental oxygen. <i>Non-hospitalized adults and pediatric patients (weighing at least 40 kg)</i> with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death. ⁴⁴
Prescribing Window	Initiate within 5 days of symptom onset ⁴³	Initiate within 7 days of symptom onset. ⁴⁴
Usual Dose <i>(mild-moderate COVID-19)</i>	<p>300 mg nirmatrelvir + 100 mg ritonavir</p> <p>Both taken together orally twice daily for 5 days ⁴³</p>	<p>Adults and pediatrics weighing ≥40 kg: ⁴⁴</p> <ul style="list-style-type: none"> Loading dose: 200 mg IV on day 1 100 mg IV on day 2 and day 3
Dosing in renal impairment*	<p>GFR 30 mL/min - 60 mL/min: 150 mg nirmatrelvir + 100 mg ritonavir both twice a day for 5 days.</p> <p>GFR <30 mL/min: 300 mg nirmatrelvir + 100 mg ritonavir both on day 1 then 150 mg nirmatrelvir + 100 mg ritonavir both once a day for 4 more days. ^{45,46}</p>	No dose adjustment required with impaired renal function, including patients on dialysis. ⁴⁷

	Nirmatrelvir/Ritonavir (Paxlovid)	Remdesivir (Veklury)
Potential for Drug Interactions	<p>Nirmatrelvir/ritonavir are major substrates of CYP3A4. Ritonavir is a potent inhibitor of CYP3A4.⁴⁸</p> <p>Resources: Liverpool’s COVID-19 Interaction Checker (link)</p> <p>University of Waterloo/University of Toronto: Nirmatrelvir/Ritonavir (Paxlovid) – What Prescribers and Pharmacists Need to Know (link)</p> <p>SHS + UHN - Paxlovid-Oncology DDI (link)</p>	<p>Minor substrate of CYP2D6, CYP3A4.⁴⁸</p> <p>Few clinically significant drug interactions</p>
Administration considerations	<p>Nirmatrelvir and ritonavir are film-coated tablets that can be crushed and administered through feeding tubes if necessary.³³</p>	<p>Remdesivir is only available as an IV formulation which requires nursing support to administer on three consecutive days.</p>
Clinically relevant Contraindications	<p>Hypersensitivity</p> <p>Severe Hepatic impairment (Child-Pugh C)⁴³</p>	<p>Hypersensitivity</p> <p>Sinus bradycardia is a precaution but not a contraindication.⁴⁴</p>

* Dosing recommendations may differ from Health Canada recommended approved dosing.

Figure 1: Treatment Algorithm for non-hospitalized adults with COVID-19



Additional resources

Visit the Ontario Health [COVID-19 treatment website](#) for the latest resources on remdesivir and other COVID-19 therapeutics, including information about how to access COVID-19 therapeutics (nirmatrelvir/ritonavir and remdesivir) for patients in the community.

For guidance on COVID-19 screening, testing visit the Ministry of Health's COVID-19 [website](#) on Guidance for the Health Sector.

Questions?

For any questions on the contents of this document, please contact the Provincial Drug Reimbursement Programs (PDRP) at OH-CCO_InfoPDRP@ontariohealth.ca.

Need this information in an accessible format? 1-877-280-8538, TTY 1-800-855-0511, info@ontariohealth.ca.

Disponible en anglais seulement suite à son exemption de la traduction en vertu de la Loi sur les services en français. Une version en français peut être fournie sur demande. Pour toute question, veuillez envoyer un courriel à info@ontariohealth.ca.

Acknowledgements/Contributors

Ontario Health's Infectious Diseases Advisory Committee Members

Name	Title
Gerald Evans (Chair)	Professor, Departments of Medicine, Biomedical & Molecular Sciences and Pathology & Molecular Medicine, Queen's University; Medical Director, Infection Prevention & Control, Kingston Health Sciences Centre
Carol-Ann Agnihotri	Primary Care Nurse Practitioner, Blind River District Health Centre
Lucas Castellani	Internal Medicine and Infectious Disease Physician and Medical Director, Infection Prevention and Control, Sault Area Hospital
Kelly Grindrod	Associate Professor, University of Waterloo School of Pharmacy
Charles Hui	Chief of the Division of the Infectious Diseases, Immunology and Allergy at the Children's Hospital of Eastern Ontario; Professor of Pediatrics, University of Ottawa
Elizabeth Leung	Clinical Pharmacy Specialist/Lead (Infectious Disease/Antimicrobial Stewardship Program), Unity Health Toronto - St. Michael's Hospital
Michaeline McGuinty	Division of Infectious Diseases, Clinician Scientist, University of Ottawa / Ottawa Hospital Research Institute
Santiago Perez-Patrigeon	Assistant Professor, Division of Infectious Diseases, Queen's University
Sumit Raybardhan	Infectious Disease Pharmacist Practitioner/Co-Lead Antimicrobial Stewardship Program, North York General Hospital
Kevin Schwartz	Head – Infectious Disease Division, Unity Health Toronto – St. Joseph's Health Centre; Co-medical director, antimicrobial stewardship, Unity Health Toronto; Assistant Professor, Dalla Lana School of Public Health, University of Toronto
Brent Wolfrom	Family Physician; Program Director at Queen's University, Department of Family Medicine

Notes: Each member of the Infectious Diseases Advisory Committee was asked to declare any actual, potential, or perceived conflicts of interest.

Infectious Diseases Advisory Committee Ex-officio members:

- Chris Simpson, Executive Vice President, Medical, Ontario Health
- Scott Gavura, Director, Provincial Drug Reimbursement Programs, Ontario Health

-
- Daniel Warshafsky, Associate Chief Medical Officer of Health, Ontario
 - Rohini Naipaul, Senior Pharmacist, Provincial Drug Reimbursement Programs, Ontario Health
 - Andrea Crespo, Senior Pharmacist, Systemic Treatment Program, Ontario Health (Guest)

Special thanks to Jaemin Kim and Pam Takhar, from the Evidence Search & Review Service, for conducting the systematic literature review.

References

1. Gottlieb RL, Vaca CE, Paredes R, et al. Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients. *New England Journal of Medicine* 2022; 386: 305–315.
2. Brown SM, Katz MJ, Ginde AA, et al. Consistent Effects of Early Remdesivir on Symptoms and Disease Progression Across At-Risk Outpatient Subgroups: Treatment Effect Heterogeneity in PINETREE Study. *Infect Dis Ther* 2023; 12: 1189–1203.
3. Mazzitelli M, Trunfio M, Sasset L, et al. Risk of hospitalization and sequelae in patients with COVID-19 treated with 3-day early remdesivir vs. controls in the vaccine and Omicron era: A real-life cohort study. *J Med Virol* 2023; 95: e28660.
4. Rajme-López S, Martínez-Guerra BA, Zalapa-Soto J, et al. Early Outpatient Treatment With Remdesivir in Patients at High Risk for Severe COVID-19: A Prospective Cohort Study. *Open Forum Infect Dis* 2022; 9: ofac502.
5. Tiseo G, Barbieri C, Galfo V, et al. Efficacy and Safety of Nirmatrelvir/Ritonavir, Molnupiravir, and Remdesivir in a Real-World Cohort of Outpatients with COVID-19 at High Risk of Progression: The PISA Outpatient Clinic Experience. *Infect Dis Ther* 2023; 12: 257–271.
6. Manciuilli T, Spinicci M, Rossetti B, et al. Safety and Efficacy of Outpatient Treatments for COVID-19: Real-Life Data from a Regionwide Cohort of High-Risk Patients in Tuscany, Italy (the FEDERATE Cohort). *Viruses* 2023; 15: 438.
7. Piccicacco N, Zeitler K, Ing A, et al. Real-world effectiveness of early remdesivir and sotrovimab in the highest-risk COVID-19 outpatients during the Omicron surge. *J Antimicrob Chemother* 2022; 77: 2693–2700.
8. Panagopoulos P, Petrakis V, Trypsianis G, et al. Early 3-day course of remdesivir in vaccinated outpatients with SARS-CoV-2 infection. A success story. *J Chemother* 2022; 34: 550–553.
9. Scotto R, Buonomo AR, Iuliano A, et al. Remdesivir Alone or in Combination with Monoclonal Antibodies as an Early Treatment to Prevent Severe COVID-19 in Patients with Mild/Moderate Disease at High Risk of Progression: A Single Centre, Real-Life Study. *Vaccines (Basel)* 2023; 11: 200.
10. Biscarini S, Villa S, Genovese C, et al. Safety Profile and Outcomes of Early COVID-19 Treatments in Immunocompromised Patients: A Single-Centre Cohort Study. *Biomedicines* 2022; 10: 2002.
11. Public Health Agency of Canada. COVID-19 vaccine: Canadian Immunization Guide, <https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/page-26-covid-19-vaccine.html> (2023, accessed 31 July 2023).
12. Solera JT, Árbol BG, Bahinskaya I, et al. Short-course early outpatient remdesivir prevents severe disease due to COVID-19 in organ transplant recipients during the omicron BA.2 wave. *Am J Transplant* 2023; 23: 78–83.

13. Gáspár Z, Szabó BG, Ábrahám A, et al. Outcomes of high-risk adult outpatients treated with early remdesivir therapy during the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) omicron era: experiences from the national centre of Hungary. *Naunyn Schmiedebergs Arch Pharmacol* 2023; 396: 1857–1862.
14. Pereta I, Morancho A, López N, et al. Hospital at home treatment with remdesivir for patients with COVID-19: real-life experience. *Int J Infect Dis* 2023; 127: 124–128.
15. Zamani S, Alizadeh M, Shahrestanaki E, et al. Prognostic comparison of COVID-19 outpatients and inpatients treated with Remdesivir: A retrospective cohort study. *PLoS One* 2022; 17: e0277413.
16. Pinargote-Celorio H, Otero-Rodríguez S, González-de-la-Aleja P, et al. Infección leve por SARS-CoV-2 en pacientes vulnerables: implantación de una vía clínica de tratamiento precoz [Mild SARS-CoV-2 infection in vulnerable patients: implementation of a clinical pathway for early treatment]. *Enfermedades Infecciosas y Microbiología Clínica* 2022; S0213005X22002828.
17. National Institutes of Health. Therapeutic Management of Nonhospitalized Adults With COVID-19. *COVID-19 Treatment Guidelines*, <https://www.covid19treatmentguidelines.nih.gov/management/clinical-management-of-adults/nonhospitalized-adults--therapeutic-management/> (2023, accessed 18 July 2023).
18. Infectious Disease Society of America (IDSA). IDSA Guidelines on the Treatment and Management of Patients with COVID-19. *IDSA*, <https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/> (2023, accessed 17 July 2023).
19. Grant JM, Chan J, Lothar SA, et al. AMMI Canada Practice Point: Treatments for adults with COVID-19 in 2021–2022. *Journal of the Association of Medical Microbiology and Infectious Disease Canada* 2022; 7: 163–169.
20. Centers for Disease Control and Prevention. Underlying Medical Conditions Associated with Higher Risk for Severe COVID-19: Information for Healthcare Professionals. *Centers for Disease Control and Prevention*, <https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/underlyingconditions.html> (February 9, 20203, accessed 19 July 2023).
21. U.S. Department of Health & Human Services. Veklury (remdesivir). A Preferred Antiviral Drug to Treat COVID-19. *ASPR -Administration for Strategic Preparedness & Response*, <https://aspr.hhs.gov:443/COVID-19/Therapeutics/Products/Veklury/Pages/default.aspx> (accessed 18 July 2023).
22. World Health Organization. Therapeutics and COVID-19: living guideline. v13.1, <https://app.magicapp.org/#/guideline/nBkO1E> (2023, accessed 24 July 2023).
23. Saskatchewan Health Authority. Outpatient COVID-19 Management. Medication and Prescribing Guidance., <https://www.saskhealthauthority.ca/system/files/2022-01/CV-19-G0165-Outpatient-COVID-19-Management.pdf> (2022, accessed 31 July 2023).
24. Alberta Health Services. FAQs for Healthcare Providers. Remdesivir (antiviral medication) Outpatient Treatment., <https://www.albertahealthservices.ca/assets/info/ppih/if-ppih-covid-19-remdesivir-faq-hcw.pdf> (2023, accessed 18 July 2023).

-
25. National Clinical Evidence Taskforce-COVID-19. Australian guidelines for the clinical care of people with COVID-19. v74.1, <https://app.magicapp.org/#/guideline/L4Q5An/rec/j96ykN> (2023, accessed 25 July 2023).
 26. Bartoletti M, Azap O, Barac A, et al. European society of clinical microbiology and infectious diseases guidelines for coronavirus disease 2019: an update on treatment of patients with mild/moderate disease. *Clin Microbiol Infect* 2022; 28: 1578–1590.
 27. Public Health Agency of Canada. An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI). Guidance on the use of COVID-19 vaccines in the fall of 2023., <https://www.canada.ca/en/public-health/services/publications/vaccines-immunization/national-advisory-committee-immunization-guidance-use-covid-19-vaccines-fall-2023.html> (2023, accessed 31 July 2023).
 28. Kaduszkiewicz H, Kochen MM, Kluge S, et al. Recommendations for the Outpatient Drug Treatment of Patients With COVID-19. *Dtsch Arztebl Int* 2022; 119: 342–349.
 29. Ontario Ministry of Health. COVID-19 Provincial Testing Guidance, https://www.health.gov.on.ca/en/pro/programs/publichealth/coronavirus/docs/covid-19_provincial_testing_guidance.pdf (2023, accessed 3 August 2023).
 30. Ontario Ministry of Health. Management of Cases and Contacts of COVID-19 in Ontario, https://www.health.gov.on.ca/en/pro/programs/publichealth/coronavirus/docs/contact_mngmt/management_cases_contacts.pdf (2023, accessed 3 August 2023).
 31. Ontario Ministry of Health. Ontario Public Health Standards: Requirements for Programs, Services and Accountability - Infectious Disease Protocol - Appendix 1: Case Definitions and Disease-Specific Information - Disease: Diseases caused by a novel coronavirus, including Coronavirus Disease 2019, https://www.health.gov.on.ca/en/pro/programs/publichealth/coronavirus/docs/2019_case_definition.pdf (2023, accessed 3 August 2023).
 32. BC COVID Therapeutics Committee. Clinical Practice Guide for the Use of Therapeutics in Mild-Moderate COVID-19, http://www.bccdc.ca/Health-Professionals-Site/Documents/COVID-treatment/ClinicalPracticeGuide_Therapeutics_MildModerateCOVID.pdf (2023, accessed 24 July 2023).
 33. BC Centre for Disease Control. BC COVID Therapeutics Committee (CTC) COVID Therapy Review and Advisory Working Group (CTRAWG) Practice Brief – Crushing nirmatrelvir/ritonavir, http://www.bccdc.ca/Health-Professionals-Site/Documents/COVID-treatment/Crushing_Paxlovid.pdf (2022, accessed 24 July 2023).
 34. National Institutes of Health. COVID-19 Treatment Guidelines. Ritonavir-Boosted Nirmatrelvir (Paxlovid). *COVID-19 Treatment Guidelines*, <https://www.covid19treatmentguidelines.nih.gov/therapies/antivirals-including-antibody-products/ritonavir-boosted-nirmatrelvir--paxlovid-/> (2023, accessed 21 July 2023).
 35. Public Health Agency of Canada. COVID-19 signs, symptoms and severity of disease: A clinician guide. Updated: 1 Jun 2022., <https://www.canada.ca/en/public-health/services/diseases/2019-novel-coronavirus-infection/guidance-documents/signs-symptoms-severity.html> (2020, accessed 19 July 2023).

-
36. Sundaram ME, Calzavara A, Mishra S, et al. Individual and social determinants of SARS-CoV-2 testing and positivity in Ontario, Canada: a population-wide study. *CMAJ* 2021; 193: E723–E734.
 37. Ma H, Chan AK, Baral SD, et al. Which Curve Are We Flattening? The Disproportionate Impact of COVID-19 Among Economically Marginalized Communities in Ontario, Canada, Was Unchanged From Wild-Type to Omicron. *Open Forum Infect Dis* 2022; 10: ofac690.
 38. McKenzie K, Dube S, Petersen S. *Tracking COVID-19 Through Race-Based Data*. Wellesley Institute; Ontario Health, <https://www.wellesleyinstitute.com/publications/tracking-covid-19/> (18 August 2021, accessed 24 July 2023).
 39. Loutfy M, Kennedy VL, Riazi S, et al. Development and assessment of a hospital-led, community-partnering COVID-19 testing and prevention program for homeless and congregate living services in Toronto, Canada: a descriptive feasibility study. *CMAJ Open* 2022; 10: E483–E490.
 40. Smylie J, McConkey S, Rachlis B, et al. Uncovering SARS-COV-2 vaccine uptake and COVID-19 impacts among First Nations, Inuit and Métis Peoples living in Toronto and London, Ontario. *CMAJ* 2022; 194: E1018–E1026.
 41. Public Health Agency of Canada. What we heard: Indigenous Peoples and COVID-19: Public Health Agency of Canada’s companion report, <https://www.canada.ca/en/public-health/corporate/publications/chief-public-health-officer-reports-state-public-health-canada/from-risk-resilience-equity-approach-covid-19/indigenous-peoples-covid-19-report.html> (2021, accessed 21 August 2023).
 42. Xia Y, Ma H, Moloney G, et al. Geographic concentration of SARS-CoV-2 cases by social determinants of health in metropolitan areas in Canada: a cross-sectional study. *CMAJ* 2022; 194: E195–E204.
 43. Pfizer Canada ULC. Paxlovid (nirmatrelvir/ritonavir). Product Monograph. Revised: 27 Jun 2023, https://pdf.hres.ca/dpd_pm/00071387.PDF (2023, accessed 18 July 2023).
 44. Gilead Sciences Canada. Veklury (Remdesivir). Product Monograph. Revised: 13 Jun 2023, https://pdf.hres.ca/dpd_pm/00071267.PDF (2023, accessed 18 July 2023).
 45. Ontario Health (Ontario Renal Network). Nirmatrelvir Ritonavir (Paxlovid) and Remdesivir Use in Patients on Dialysis with COVID-19 Quick Reference Guide. Updated: 1 Dec 2022., <https://www.ontariohealth.ca/sites/ontariohealth/files/2022-12/NirmatrelvirRitonavir-Paxlovid-RemdesivirUsePatientsDialysisCOVID-19QuickReferenceGuide.pdf> (2022, accessed 24 July 2023).
 46. Ontario Health (Ontario Renal Network). Nirmatrelvir/Ritonavir (Paxlovid) use in patients with advanced chronic kidney disease and patients on dialysis with COVID-19. 13 April 2022., <https://www.ontariohealth.ca/sites/ontariohealth/files/2022-04/PaxlovidClinicalGuide.pdf> (2022, accessed 24 July 2023).
 47. Gilead Sciences. Veklury (remdesivir). U.S. Prescribing Information., https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/214787s019lbl.pdf (2023, accessed 24 July 2023).

-
48. Lexicomp Online, Pediatric and Neonatal Lexi-Drugs Online. *UptoDate*, <https://online.lexi.com>. (accessed 31 July 2023).